Cleary Gottlieb represented Blackstone in the formation of Blackstone Life Sciences Yield (BXLS Yield), its inaugural royalty and structured credit-focused life sciences fund.
The fund was oversubscribed and is the largest first-time fund of this nature. It closed with $1.6 billion of investor capital focused on post-approval, commercial-stage opportunities. It complements the flagship strategy of BXLS, which invests in late-stage product development. Together, the two pools of capital enable BXLS to support end-to-end life science innovation at scale and showcase Blackstone’s deep conviction in this sector.
For more information, please see the press release here.